Administration of Dexmedetomidine Guided by Entropy/SPI Reduce

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexmedetomidine, a selective alpha2-adrenergic agonist is known to reduce propofol and opioid requirements due to its sedative and analgesic properties. However, until now, there has been studies based on indirect measures such as hemodynamics. Entropy shows to quantify the level of consciousness by EEG and Surgical pleth index(SPI) allows to predict the effect of pain stimuli and analgesic therapy by the index of the nociception-anti-nociception balance. The investigators analyzed quantitatively the requirements of propofol and remifentanil under continuous infusion of dexmedetomidine when using entropy and SPI.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1.The patients (20~65 years old, ASA class 1 or 2) scheduled lumbar discectomy under general anesthesia

Exclusion Criteria:

1. ASA class (American Society of Anesthesiologist physical status classification) 3 or higher

2. Patients with history of allergy or side effects on propofol, remifentanil, dexmedetomidine

3. BMI (body mass index) higher than 35

4. Patients taking monoamine oxidase inhibitor or adrenergic blocking agent

5. Pregnancy, Emergency operation

6. Patients with liver disease, cognitive dysfunction or drug abuse history